Skip Navigation Links

Eli Lilly | Strategy and Financial Highlights Information from ICIS

 

Edited from 'Letter to shareholders' - annual report

 

On the back of another challenging market place, Eli Lilly states that this was due to the intense pressures put on the pharmaceutical industry, such as the general struggle for people to afford the costs of health care and drugs in particular on a worldwide level. Other factors include an ‘aging population’ that is said to be ‘straining health care budgets’.

 

In addition, there has been a withdrawal of some antidepressants that have been associated with suicidal thoughts. The withdrawal of Merck’s painkiller drug Vioxx has highlighted a backlash of concerns over product safety and this in turn has made regulatory agencies more cautious.

 

Looking ahead, Eli Lilly will focus on its ‘innovation-driven’ strategy. ‘We chose to remain independent; to invest in R&D at the top of the industry with the goal of delivering a steady flow of innovative products; to build the capabilities to manufacture these products and market them effectively around the world; and to augment our own capabilities and resources through partnerships’, says chairman and chief executive officer, Sidney Taurel.


The company has built what it states as being ‘one of the most productive R&D organisations in the pharmaceutical industry’. It is currently readying a generation of molecules for the market and restocking its early-stage pipeline. It states that ‘unlike most of its peers’, it does not have any major patent expirations coming up in the next several years. Its strength in developing both small-molecule and large-molecule ‘biotech’ medicines is said to also distinguish Eli Lilly from most other major pharmaceutical companies.

 

The company has a number of ‘promising’ molecules in its near-term pipeline. Its application to market Arxxant has been submitted to the FDA. If approved, it would be the first pharmaceutical treatment for moderate to severe non-proliferative diabetic retinopathy, a microvascular complication associated with diabetes that can cause vision loss or, eventually, blindness. It is also studying Arxxant for the treatment of other serious complications of diabetes.

 

The company is also developing prasugrel, in collaboration with Sankyo, for acute coronary syndromes. It is comparing its effectiveness with that of the cardiovascular medicine clopidogrel in a phase III head-to-head study. The goal of this study is to determine whether prasugrel, a platelet inhibitor that works by preventing clots and its complications can do a better job reducing death, heart attacks, and stroke in high-risk patients undergoing coronary stent placement.

 

Enzastaurin for regulating tumour cell survival, and possibly for the treatment of non-Hodgkin’s lymphoma and other tumours is also being studied.

 

The company believes that it has the ‘right strategy for the future’.  While many aspects of its business environment will remain ‘uncertain’, the key to success is stated as being ‘clear’. It is believed that ‘the winners will be those companies that consistently deliver innovative medicines valued by patients, providers and payers, and continually elevate its productivity and flexibility’.

 

Its strategic focus on innovation provides the platform from which to leverage its advances in life sciences. The company has begun to pursue the development of ‘tailored therapeutics’ through the application of new tools and technologies, such as pharmacogenomics and biomarkers, biological telltales like blood sugar levels in people with diabetes that signal specific diseases. ‘Establishing this new model will take years. To invest in this transformation, we must dramatically improve the productivity of our current business model’, concludes Taurel.

 

Please also see Interview: Evonik proceeds with integrating Eli Lilly deal on ICIS news.

 

Download the The ICIS Top 100 Chemical Companies listing here

 

Financial highlights: Eli Lilly, year ended 31 December

 

2009

 2008

 2007

 2006

 2005

Sales ($ m)

21,836

20,372

18,633.5

15,691

14,645

R&D ($ m)

4,326.5

3,841

3,487

3,129

3,026

Net Profit ($ m)

4,329

-2,072

2,953

2,663

1,980

Total Assets ($ m)

--

--

26,788

21,955

24,581

Diluted earnings per share ($)

3.94

-1.89

2.71 

2.45

1.82

Number of Employees

40,360

40,450

40,600

41,500

42,600

 

Currency Converter by OANDA.com, The Currency Site.

Eli Lilly Company Structure

Eli Lilly is a major pharmaceutical corporation which develops pharmaceutical products. The company has major R&D facilities in seven countries. Its R&D facilities are located in Australia, Belgium, Canada, England, Germany, Japan, Singapore, Spain, and the US. It conducts clinical research in more than 60 countries around the world. Manufacturing facilities are located in Brazil, China, Egypt, England, France, Germany, Ireland, Italy, Japan, Korea, Mexico, Pakistan, Puerto Rico, Spain and the US. In addition Eli Lilly operates 14 administrative, manufacturing and R&D plants in the US and Puerto Rico.
More about Eli Lilly Structure

News:

Get news on Eli Lilly plus the latest chemical news, information, data, market movements and analysis in one place with ICIS news

Search:

Find details on other chemical companies and suppliers with ICIS search

Newsletters:

ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.

Plants and projects:

Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database

 
Free trial to ICIS
Paul Hodges - Chemicals & the Economy Blog
Paul Hodges looks behind today's headlines and studies key influencers shaping the chemical industry over the next 12-18 months. He takes a closer look at oil prices, economic growth and the environment among other things, along with some light-hearted banter along the way.

Insight

INSIGHT: China’s apparent PE demand is too good to be true
“China’s PE demand on an apparent basis was up by a staggering a 25% in January-May this year over the same period in 2012.” more

VIDEO: ICIS Special Report - Asia methanol, acetic acid

More...

We welcome your feedback. Please feel free to send us your comments on any aspect of this site. Click here to make your comments.